Galena Biopharma to Present at the 17th Annual BIO CEO & Investor Conference
January 28 2015 - 7:05AM
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company
developing and commercializing innovative, targeted oncology
treatments that address major medical needs across the full
spectrum of cancer care, today announced that Mark W. Schwartz,
Ph.D., President and Chief Executive Officer will present a
corporate update at the 17th Annual BIO CEO & Investor
Conference. The presentation will take place on Tuesday, February
10, 2015 at 11:00 a.m. ET at The Waldorf Astoria Hotel in New York,
NY.
The presentation will be webcast and available on the Investors
section of the Company's website at www.galenabiopharma.com.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a biopharmaceutical
company developing and commercializing innovative, targeted
oncology therapeutics that address major medical needs across the
full spectrum of cancer care. Galena's development portfolio ranges
from mid- to late-stage clinical assets, including a robust
immunotherapy program led by NeuVax™ (nelipepimut-S) currently in
an international, Phase 3 clinical trial. The Company's commercial
drugs include Abstral® (fentanyl) Sublingual Tablets and Zuplenz®
(ondansetron) Oral Soluble Film. Collectively, Galena's clinical
and commercial strategy focuses on identifying and advancing
therapeutic opportunities to improve cancer care, from direct
treatment of the disease to the reduction of its debilitating
side-effects. For more information,
visit www.galenabiopharma.com.
CONTACT: Remy Bernarda
Vice President, Marketing & Communications
(503) 405-8258
rbernarda@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024